Source: FirstWord Pharma

Istesso: Istesso announces initiation of Phase 2b trial of MBS2320

MBS2320 administered to participants with moderate-to-severe Rheumatoid Arthritis Istesso Limited, the immunometabolism drug discovery and development company, today announces the initiation ...

Read full article »
Istesso's Competitors | Istesso's News | Istesso's Financials
Stay up-to-date with the latest news on Istesso
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Sam Williams's photo - Chairman & CEO of Istesso

Chairman & CEO

Sam Williams

CEO Approval Rating

83/100

Read more
Stay up-to-date with the latest news on Istesso